RenovoRx Inc., a NASDAQ-listed company, has shared insights from its recent investor presentation. The company is advancing its proprietary Trans-Arterial Micro-Perfusion (TAMP) platform, which combines RenovoCath with Gemcitabine for treating pancreatic and bile duct cancers. This combination has received FDA Orphan Drug Designation. RenovoRx has initiated the commercialization of its FDA-cleared RenovoCath device, with revenues in the first half of 2025 exceeding expectations. Currently, four cancer centers are using the device, with more than 20 potential customers in discussions. The ongoing Phase III TIGeR-PaC study for locally advanced pancreatic cancer has shown promising results, with a significant reduction in adverse effects. The study's enrollment is expected to conclude by late 2025 or early 2026. RenovoRx aims to pursue a potential peak annual U.S. revenue opportunity of approximately $400 million for RenovoCath as a stand-alone device, with plans to expand its applications further. You can access the full presentation through the link below.